Design Therapeutics Q3 net loss beats estimates; sees DT-216P2 data in Q1
DSGN•Design Therapeutics reported a third-quarter net loss of $20.29 million, narrower than the $21.84 million analyst consensus, though the loss widened year over year. The company ended the quarter with $208.6 million in cash and securities and expects 12-week DT-216P2 data in Q1 2027.
1. Quarterly results
Design Therapeutics reported a Q3 net loss of $20.29 million, or $0.32 per basic share, compared with the $21.84 million analyst consensus. Operating expenses rose to $22.23 million, including higher research and development and general and administrative costs; other income fell to $1.9 million from $2.3 million. The company ended the quarter with $208.6 million in cash and securities.
2. Clinical program outlook
The company expects to update its DT-216P2 registrational plans in Q4 2026 and anticipates reporting 12-week RESTORE-FA data for DT-216P2 in Q1 2027. It also expects to report Phase 1 DT-818 data for DM1 in 2027.
